Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

The FDA has granted Fast Track designation to LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis.

Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

EET Orion's collaboration partner Bayer submits application in China for third indication of darolutamide Orion's collaboration ...

PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a ...

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease missed by conventional imaging, investigators report.

A study led by UCLA Health Jonsson Comprehensive Cancer Center, published in JAMA Network Open, shows that nearly half of the patients classified as nonmetastatic by conventional imaging were found to ...